Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

J. Ludovic Croxford, Gareth Pryce, Samuel J. Jackson, Catherine Ledent, Gavin Giovannoni, Roger G. Pertwee, Takashi Yamamura, David Baker

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Cannabinoids may exhibit symptom control in multiple sclerosis (MS). We show here that cannabinoid receptor (CBR) agonists can also be immunosuppressive and neuroprotective in models of MS. Immunosuppression was associated with reduced: myelin-specific T cell responses; central nervous system infiltration and reduced clinical disease. This was found to be largely CB1R-dependent and only occurred at doses that induced significant cannabimimetic effects that would not be achieved clinically. Lower, non-immunosuppressive doses of cannabinoids however, slowed the accumulation of nerve loss and disability, despite failing to inhibit relapses. This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS. (C) 2007 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)120-129
Number of pages10
JournalJournal of Neuroimmunology
Volume193
Issue number1-2
Early online date26 Nov 2007
DOIs
Publication statusPublished - Jan 2008

Keywords

  • cannabinoids
  • experimental autoimmune encephalomyelitis
  • multiple sclerosis
  • immunosuppression
  • neuroprotection
  • placebo-controlled trial
  • CB2 receptor
  • glucocorticoid-receptors
  • endocannabinoid system
  • disease progression
  • interferon-gamma
  • ajulemic acid
  • model
  • agonist

Cite this

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. / Croxford, J. Ludovic; Pryce, Gareth; Jackson, Samuel J.; Ledent, Catherine; Giovannoni, Gavin; Pertwee, Roger G.; Yamamura, Takashi; Baker, David.

In: Journal of Neuroimmunology, Vol. 193, No. 1-2, 01.2008, p. 120-129.

Research output: Contribution to journalArticle

Croxford, JL, Pryce, G, Jackson, SJ, Ledent, C, Giovannoni, G, Pertwee, RG, Yamamura, T & Baker, D 2008, 'Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis', Journal of Neuroimmunology, vol. 193, no. 1-2, pp. 120-129. https://doi.org/10.1016/j.jneuroim.2007.10.024
Croxford, J. Ludovic ; Pryce, Gareth ; Jackson, Samuel J. ; Ledent, Catherine ; Giovannoni, Gavin ; Pertwee, Roger G. ; Yamamura, Takashi ; Baker, David. / Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. In: Journal of Neuroimmunology. 2008 ; Vol. 193, No. 1-2. pp. 120-129.
@article{34f5558ec14046d4bf74545791aedc7a,
title = "Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis",
abstract = "Cannabinoids may exhibit symptom control in multiple sclerosis (MS). We show here that cannabinoid receptor (CBR) agonists can also be immunosuppressive and neuroprotective in models of MS. Immunosuppression was associated with reduced: myelin-specific T cell responses; central nervous system infiltration and reduced clinical disease. This was found to be largely CB1R-dependent and only occurred at doses that induced significant cannabimimetic effects that would not be achieved clinically. Lower, non-immunosuppressive doses of cannabinoids however, slowed the accumulation of nerve loss and disability, despite failing to inhibit relapses. This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS. (C) 2007 Elsevier B.V. All rights reserved.",
keywords = "cannabinoids, experimental autoimmune encephalomyelitis, multiple sclerosis, immunosuppression, neuroprotection, placebo-controlled trial, CB2 receptor, glucocorticoid-receptors, endocannabinoid system, disease progression, interferon-gamma, ajulemic acid, model, agonist",
author = "Croxford, {J. Ludovic} and Gareth Pryce and Jackson, {Samuel J.} and Catherine Ledent and Gavin Giovannoni and Pertwee, {Roger G.} and Takashi Yamamura and David Baker",
year = "2008",
month = "1",
doi = "10.1016/j.jneuroim.2007.10.024",
language = "English",
volume = "193",
pages = "120--129",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

AU - Croxford, J. Ludovic

AU - Pryce, Gareth

AU - Jackson, Samuel J.

AU - Ledent, Catherine

AU - Giovannoni, Gavin

AU - Pertwee, Roger G.

AU - Yamamura, Takashi

AU - Baker, David

PY - 2008/1

Y1 - 2008/1

N2 - Cannabinoids may exhibit symptom control in multiple sclerosis (MS). We show here that cannabinoid receptor (CBR) agonists can also be immunosuppressive and neuroprotective in models of MS. Immunosuppression was associated with reduced: myelin-specific T cell responses; central nervous system infiltration and reduced clinical disease. This was found to be largely CB1R-dependent and only occurred at doses that induced significant cannabimimetic effects that would not be achieved clinically. Lower, non-immunosuppressive doses of cannabinoids however, slowed the accumulation of nerve loss and disability, despite failing to inhibit relapses. This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS. (C) 2007 Elsevier B.V. All rights reserved.

AB - Cannabinoids may exhibit symptom control in multiple sclerosis (MS). We show here that cannabinoid receptor (CBR) agonists can also be immunosuppressive and neuroprotective in models of MS. Immunosuppression was associated with reduced: myelin-specific T cell responses; central nervous system infiltration and reduced clinical disease. This was found to be largely CB1R-dependent and only occurred at doses that induced significant cannabimimetic effects that would not be achieved clinically. Lower, non-immunosuppressive doses of cannabinoids however, slowed the accumulation of nerve loss and disability, despite failing to inhibit relapses. This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS. (C) 2007 Elsevier B.V. All rights reserved.

KW - cannabinoids

KW - experimental autoimmune encephalomyelitis

KW - multiple sclerosis

KW - immunosuppression

KW - neuroprotection

KW - placebo-controlled trial

KW - CB2 receptor

KW - glucocorticoid-receptors

KW - endocannabinoid system

KW - disease progression

KW - interferon-gamma

KW - ajulemic acid

KW - model

KW - agonist

U2 - 10.1016/j.jneuroim.2007.10.024

DO - 10.1016/j.jneuroim.2007.10.024

M3 - Article

VL - 193

SP - 120

EP - 129

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -